Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools
Log in
Sections
You are here: Home › Training › Seminars and Symposia › Drugging the cancer genome: large-scale objective assessment of potential targets and discovery of chaperone/stress pathway inhibitors

Drugging the cancer genome: large-scale objective assessment of potential targets and discovery of chaperone/stress pathway inhibitors

Professor Paul Workman, PhD, DSc, (Hon) FMedSci, FSB, FRSC, Deputy Chief Executive, The Institute of Cancer Research, Head, Division of Cancer Therapeutics, Director, Cancer Research UK Cancer Therapeutics Unit, Harrap Professor of Pharmacology and Therapeutics
When Jan 23, 2013
from 04:00 PM to 05:00 PM
Where 00-002 Joseph S. Pagano Conference Room, UNC Lineberger Cancer Center
Add event to calendar vCal
iCal

UNC Lineberger Cancer Center Weekly Seminar Series